These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 37583422)

  • 1. Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a meta-analysis based on mixed-effect models.
    Zheng J; Deng Y; Huang B; Chen X
    Front Med (Lausanne); 2023; 10():1198950. PubMed ID: 37583422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of immune checkpoint inhibitors plus platinum-etoposide
    Chen Y; Shang H; Yang Y; Wang Q; Gao X; Huang G
    Transl Cancer Res; 2024 Aug; 13(8):4146-4158. PubMed ID: 39262463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
    Zhang S; Li S; Cheng Y
    Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy in patients with extensive-stage small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
    Chen C; Tian P; Zhong J; Fan X
    Front Oncol; 2023; 13():1151769. PubMed ID: 37152041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
    Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis.
    Du J; Wang X; Fan L; Shan X; Li M; Liu L
    Heliyon; 2023 Apr; 9(4):e14794. PubMed ID: 37095958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.
    Yu H; Chen P; Cai X; Chen C; Zhang X; He L; Zhou Y; Hong S; Zhang B
    Cancer Immunol Immunother; 2022 Mar; 71(3):637-644. PubMed ID: 34297160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining PD-1 or PD-L1 inhibitors with chemotherapy is a good strategy for the treatment of extensive small cell lung cancer: A retrospective analysis of clinical studies.
    Luo H; Song G; Wang D; Li M; Dai N
    Front Immunol; 2022; 13():1059557. PubMed ID: 36544769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of first-line PD-L1/PD-1 inhibitors in limited-stage small cell lung cancer: a multicenter propensity score matched retrospective study.
    Xie J; Xu K; Cai Z; Chen M; Jiang Y; Ye J; Lin X; Lv T; Zhan P
    Transl Lung Cancer Res; 2024 Mar; 13(3):526-539. PubMed ID: 38601454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of thoracic radiotherapy in extensive-stage small-cell lung cancer patients receiving first-line immunotherapy plus chemotherapy: a propensity score matched multicentre retrospective analysis.
    Yao Y; Li B; Song R; Yang L; Zou B; Wang L
    Radiat Oncol; 2024 Feb; 19(1):25. PubMed ID: 38413988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis.
    Zhang T; Li W; Diwu D; Chen L; Chen X; Wang H
    Front Immunol; 2023; 14():1197044. PubMed ID: 37435087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.
    Qu J; Kalyani FS; Shen Q; Yang G; Cheng T; Liu L; Zhou J; Zhou J
    J Oncol; 2022; 2022():3645489. PubMed ID: 36199793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
    Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L
    JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis.
    Chen J; Wang J; Xu H
    Medicine (Baltimore); 2021 Apr; 100(15):e25180. PubMed ID: 33847617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer.
    Zhou F; Zhao W; Gong X; Ren S; Su C; Jiang T; Zhou C
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of addition immune checkpoint inhibitors to chemotherapy as first-line treatment for small cell lung cancer patients with liver or brain metastases: a systematic review and meta-analysis.
    Chen CR; Qi WX; Liu T; Tong X
    Eur Rev Med Pharmacol Sci; 2022 Aug; 26(16):5857-5867. PubMed ID: 36066161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis.
    Arriola E; González-Cao M; Domine M; De Castro J; Cobo M; Bernabé R; Navarro A; Sullivan I; Trigo JM; Mosquera J; Crama L; Isla D
    Oncol Ther; 2022 Jun; 10(1):167-184. PubMed ID: 35032007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
    Melosky B; Cheema PK; Brade A; McLeod D; Liu G; Price PW; Jao K; Schellenberg DD; Juergens R; Leighl N; Chu Q
    Oncologist; 2020 Nov; 25(11):981-992. PubMed ID: 32860288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing strategy of immune checkpoint inhibitors plus chemotherapy with chemotherapy alone for small cell lung cancer: a meta-analysis based on six RCTs incorporating 2800 participants.
    Zhong Y; Wu Q; Wu S; Xie X
    J Cancer Res Clin Oncol; 2022 Sep; 148(9):2465-2474. PubMed ID: 34533625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
    Liang X; Chen X; Li H; Li Y
    Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.